Chronic progressive multiple sclerosis
MONDO:0005284A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914)
158 clinical trials for this condition and its sub-types, 81 tagged with Chronic progressive multiple sclerosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Chronic progressive multiple sclerosis
-
Secondary progressive multiple sclerosis 65 trials
-
Primary progressive multiple sclerosis 57 trials
-
Could a stem cell transplant tame Hard-to-Control MS?
Disease control Recruiting nowThis study compares a stem cell transplant (using a person's own cells) against the best available medications for people with relapsing multiple sclerosis that hasn't responded to treatment. About 156 participants will be randomly assigned to one of the two approaches and follow…
Phase 3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New pill could slow MS disability in major trial
Disease control Recruiting nowThis Phase 3 trial tests an oral drug called orelabrutinib against a placebo in about 990 people with non-active secondary progressive multiple sclerosis (MS). The goal is to see if the drug can delay worsening disability over 24 to 60 months. Participants are randomly assigned t…
Phase 3 • Sponsor: Zenas BioPharma (USA), LLC • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New oral drug could slow MS progression in major trial
Disease control Recruiting nowThis phase 3 trial tests whether the oral drug orelabrutinib can slow disability progression in people with primary progressive multiple sclerosis (PPMS). About 705 adults aged 18–60 with PPMS will receive either orelabrutinib or a placebo for up to 5 years. The study measures ti…
Phase 3 • Sponsor: Zenas BioPharma (USA), LLC • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Cancer drug ixazomib tested as potential MS treatment
Disease control Recruiting nowThis phase 1b trial is testing whether ixazomib, a drug already used for multiple myeloma, is safe for people with multiple sclerosis. The study will enroll 72 adults with relapsing-remitting or progressive MS. Participants will receive either ixazomib or a placebo for up to 24 m…
Phase 1 • Sponsor: Queen Mary University of London • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
MS patients may soon get a simpler shot option
Disease control Recruiting nowThis study looks at whether people with multiple sclerosis can safely switch from their current anti-CD20 therapy to a new under-the-skin version of ocrelizumab. About 100 participants will be followed for up to 48 weeks to see if brain lesions stay stable and if they are satisfi…
Phase 4 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can biomarkers guide MS treatment? new trial aims to find out
Disease control Recruiting nowThis study tests whether changes in spinal fluid biomarkers can predict which drug or drug combination works best for people with progressive multiple sclerosis (MS). Participants will take one or two of five drugs (cilostazol, leucovorin, pirfenidone, dantrolene, or pioglitazone…
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New combo therapy aims to slow progressive MS disability
Disease control Recruiting nowThis study tests whether adding a new drug (RO7268489) to the standard MS treatment ocrelizumab can slow disability progression in adults with progressive multiple sclerosis. About 360 participants will receive either the new drug or a placebo, and researchers will track walking …
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New CAR-T therapy targets tough MS cases in early safety trial
Disease control Recruiting nowThis early study tests a new treatment called S103 (BCMA-CAR T cells) in 9 adults with progressive or hard-to-treat multiple sclerosis (MS). The main goal is to see if the treatment is safe and to find the best dose. Researchers will also look for early signs that it might help c…
Phase 1 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New pill could slow MS progression in major trial
Disease control Recruiting nowThis Phase 3 study tests whether the drug remibrutinib can slow disability worsening in people with secondary progressive multiple sclerosis (SPMS). About 1,275 adults aged 18-65 with SPMS and recent disability progression will receive either remibrutinib or a placebo. The main g…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Allergy pill shows promise for MS repair in small trial
Disease control Recruiting nowThis study tests whether clemastine fumarate, a common allergy medicine, can help repair the protective coating around nerves (myelin) in people with multiple sclerosis. About 74 adults with relapsing-remitting MS will receive either the drug or a placebo, and advanced MRI scans …
Phase 1/2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
CAR t therapy takes on lupus, MS, and more in first human safety trial
Disease control Recruiting nowThis early-stage study tests a new treatment called HBI0101 CAR T for people with severe autoimmune diseases like lupus, multiple sclerosis, and rheumatoid arthritis that haven't improved with standard treatments. The main goal is to find a safe dose and check for side effects in…
Phase 1 • Sponsor: Polina Stepensky • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could CAR T-Cells halt progressive MS? early trial launches
Disease control Recruiting nowThis early-stage trial is testing a new treatment called obe-cel, a type of cell therapy (CAR T-cell), for people with progressive multiple sclerosis (MS) that hasn't improved with standard treatments. The main goal is to see if it's safe, but researchers will also look for any s…
Phase 1 • Sponsor: Autolus Limited • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could donor cells stop MS progression? early trial launches
Disease control Recruiting nowThis early-stage trial tests a cell therapy called TRX319 in 39 adults with progressive multiple sclerosis (MS). The goal is to see if it is safe and to find the best dose. Participants receive TRX319 infusions, sometimes after a chemotherapy drug called bendamustine, and are fol…
Phase 1/2 • Sponsor: Tr1X, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Can a cancer drug sharpen the mind and hands in advanced MS?
Disease control Recruiting nowThis study tests whether rituximab, a drug used for certain cancers and autoimmune diseases, can improve thinking and hand function in people with advanced secondary progressive multiple sclerosis (SPMS). About 46 participants with high disability will receive either rituximab or…
Phase 2 • Sponsor: Cairo University • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Experimental CAR-T therapy takes on progressive MS
Disease control Recruiting nowThis early-stage trial tests a personalized cell therapy called KYV-101 for people with progressive forms of multiple sclerosis (MS) that are not responding to standard treatments. The therapy uses a patient's own immune cells, modified to target and destroy certain immune cells …
Phase 1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Can a VR forest lift your mood? new study tests nature walks for MS depression
Symptom relief Recruiting nowThis study explores whether using a virtual reality headset to experience nature scenes can help reduce depression in people with progressive multiple sclerosis. About 40 participants will use the Apple Vision Pro at home for short sessions over 8 weeks. The goal is to see if thi…
Sponsor: University of Michigan • Aim: Symptom relief
Last updated Jun 27, 2026 09:04 UTC
-
Can a home balance game boost brain and body in MS?
Symptom relief Recruiting nowThis study tests a home-based balance training program for people with multiple sclerosis (MS). The program combines stepping games, strength, and thinking tasks. Researchers will compare it to a simple stretching routine in 75 adults with MS to see if it improves physical functi…
Sponsor: University of Illinois at Chicago • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Electric sleeve aims to steady MS Patients' steps
Symptom relief Recruiting nowThis study tests a wearable device called the Cionic Neural Sleeve that uses mild electrical pulses to help leg muscles contract at the right time during walking. Fourteen people with multiple sclerosis will wear the sleeve for six weeks and also do a walking program. Researchers…
Sponsor: Cionic, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Mountain-Air breathing trick may boost MS muscle strength
Knowledge-focused Recruiting nowThis study tests whether breathing short bursts of low-oxygen air (like at high altitude) can improve ankle strength and brain activity in people with multiple sclerosis. Twenty-one adults with relapsing forms of MS will undergo 15 cycles of low oxygen followed by normal air in o…
Sponsor: Shirley Ryan AbilityLab • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Scientists probe Sleep's role in MS fatigue and brain fog
Knowledge-focused Recruiting nowThis study looks at how sleep issues contribute to tiredness and thinking problems in people with multiple sclerosis (MS). About 382 MS patients and a control group without MS will have overnight sleep tests, thinking assessments, and questionnaires. The goal is to better underst…
Sponsor: Heinrich-Heine University, Duesseldorf • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Breathing trick may boost brain power in MS patients
Knowledge-focused Recruiting nowThis study tests whether a breathing technique called Acute Intermittent Hypoxia (AIH) can help improve arm and hand function in people with multiple sclerosis (MS). Participants will breathe short bursts of low-oxygen air while researchers measure brain signals and muscle streng…
Sponsor: Shirley Ryan AbilityLab • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
New brain scan study aims to improve MS diagnosis and monitoring
Knowledge-focused Recruiting nowThis study looks at how the brain uses sugar (glucose) in people with multiple sclerosis (MS) compared to healthy volunteers. Researchers will use a special PET scan to measure brain activity and compare it with MRI scans and blood tests. The goal is to find better ways to diagno…
Phase 4 • Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Smartphone app and biobank join forces to decode MS progression
Knowledge-focused Recruiting nowThis study is collecting health data, smartphone app measurements, and biological samples from 100 people with multiple sclerosis. Researchers aim to find new biomarkers and digital tools to better understand how MS progresses and when it changes form. The goal is to improve moni…
Sponsor: University Hospital, Basel, Switzerland • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Your Phone's selfie camera could be the new MS monitor
Knowledge-focused Recruiting nowThis study looks at whether short selfie videos taken on a phone can accurately measure walking and speech changes in people with multiple sclerosis (MS). About 300 adults with MS will record 5 videos every 3 months for a year and also attend some in-person visits. The goal is to…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC